|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 USD | +9,900.00% |
|
0.00% | -99.76% |
| 04-26 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
| 04-02 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
Biocept, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 0.673 million compared to USD 19.95 million a year ago. Net loss was USD 7.14 million compared to USD 2.21 million a year ago.
Basic loss per share from continuing operations was USD 12.3 compared to USD 3.9 a year ago. Diluted loss per share from continuing operations was USD 12.3 compared to USD 3.9 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -99.76% | 2 | |
| -4.57% | 12.32B | |
| -4.35% | 8.1B | |
| +8.91% | 5.87B | |
| +29.87% | 5.52B | |
| -7.42% | 4.29B | |
| -54.16% | 3.16B | |
| +14.44% | 2.72B | |
| -2.21% | 2.37B | |
| +30.04% | 2.23B |
BIOCEPT, INC. 
